OrthoPediatrics (NASDAQ:KIDS) Sets New 12-Month Low After Analyst Downgrade

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) shares reached a new 52-week low on Monday after Truist Financial lowered their price target on the stock from $26.00 to $24.00. Truist Financial currently has a hold rating on the stock. OrthoPediatrics traded as low as $20.72 and last traded at $20.98, with a volume of 10700 shares traded. The stock had previously closed at $21.16.

Several other research analysts have also recently weighed in on KIDS. Lake Street Capital began coverage on OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price objective on the stock. Stifel Nicolaus cut their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $37.00.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares in the company, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now directly owns 110,767 shares in the company, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its position in OrthoPediatrics by 175.0% during the first quarter. SG Americas Securities LLC now owns 20,039 shares of the company's stock valued at $494,000 after purchasing an additional 12,753 shares during the last quarter. GAMMA Investing LLC increased its position in shares of OrthoPediatrics by 4,618.2% during the 1st quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock valued at $261,000 after purchasing an additional 10,391 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of OrthoPediatrics by 20.2% during the 4th quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock valued at $24,601,000 after buying an additional 178,078 shares in the last quarter. AWM Investment Company Inc. lifted its position in OrthoPediatrics by 14.8% in the 4th quarter. AWM Investment Company Inc. now owns 516,794 shares of the company's stock worth $11,979,000 after buying an additional 66,779 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in OrthoPediatrics by 76.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,863 shares of the company's stock worth $460,000 after buying an additional 8,631 shares in the last quarter. Institutional investors own 69.05% of the company's stock.

OrthoPediatrics Price Performance

The firm has a market capitalization of $510.03 million, a P/E ratio of -17.07 and a beta of 1.17. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The business's 50-day simple moving average is $23.87 and its 200 day simple moving average is $24.58.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.67 million for the quarter, compared to the consensus estimate of $51.16 million. During the same period in the previous year, the firm earned ($0.23) EPS. Sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.